Morphine withdrawal syndrome: Involvement of the dopaminergic system in prepubertal male and female mice

Pharmacology Biochemistry and Behavior

Volumn 82, Issue 4, 2005, Pages 601-607

  Diaz, Silvina L ^b   Kemmling, Alma K ^b   Rubio, Modesto C ^b   Balerio, Graciela N ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b NONE

Author keywords

Dopamine; Frontal cortex; Mice; Naloxone precipitated withdrawal; Raclopride; SCH 23390; Sex differences; Striatum

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; MORPHINE; NALOXONE; RACLOPRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC SYSTEM; DRUG MECHANISM; ELECTROCHEMICAL DETECTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; MALE; MORPHINE WITHDRAWAL SYNDROME; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PREPUBERTY; PRIORITY JOURNAL; SEX DIFFERENCE; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DOPAMINE; FEMALE; MALE; MICE; MORPHINE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SEXUAL MATURATION; SUBSTANCE WITHDRAWAL SYNDROME;

ANIMALIA;

EID: 31844443873     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2005.10.012     Document Type: Article

References (39)

1. E. Acquas, and G. Di Chiara Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence J Neurochem 58 1992 1620 1625
2. E. Acquas, E. Carboni, and G. Di Chiara Profound depression of mesolimbic dopamine release after morphine withdrawal in dependent rats Eur J Pharmacol 193 1991 133 134
3. V. Bassareo, G. Tanda, and G. Di Chiara Increase of extracellular dopamine in the medial prefrontal cortex during spontaneous and naloxone-precipitated opiate-abstinence Psychopharmacology (Berlin) 122 1995 202 205
4. S.M. Breedlove Sexual differentiation of the vertebrate nervous system J Neurosci 12 1992 4133 4142
5. B.S. Bunney The electrophysiological pharmacology of mid-brain dopaminergic systems A.S. Horn J.K. Koff B.H.C. Westernik The neurobiology of dopamine 1979 Academic Press New York 417 452
6. D.L. Cameron, and J.T. Williams Dopamine D1 receptors facilitate transmitter release Nature 366 1993 344 347
7. J. Candido, K. Lutfy, B. Billings, V. Sierra, A. Duttaroy, and C.E. Inturrisi Effect of adrenal and sex hormones on opioid analgesia and opioid receptor regulation Pharmacol Biochem Behav 42 1992 685 692
8. T.J. Cicero, B. Nock, and E.R. Meyer Sex-related differences in the morphine's antinociceptive activity: relationship to serum and brain morphine concentrations J Pharmacol Exp Ther 282 1997 939 944
9. A.R. Cools, L.C. Gieles, H.J. Janssen, and A.A. Megens Morphine and its biphasic influence upon pharmacologically distinct dopaminergic systems within the feline caudate nucleus: a behavioural study Eur J Pharmacol 48 1978 67 85
10. R.M. Craft, J.A. Stratmann, R.E. Bartok, T.I. Walpole, and S.J. King Sex differences in development of morphine tolerance and dependence in rat Psychopharmacology 143 1999 1 7
11. M. Diana, M. Pistis, A. Muntoni, and G. Gessa Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats J Pharmacol Exp Ther 272 1995 781 785
12. S.L. Diaz, A.K. Kemmling, M.C. Rubio, and G.N. Balerio Lack of sex-related differences in the prevention by baclofen of the morphine withdrawal syndrome in mice Behav Pharmacol 12 2001 75 79
13. S.L. Diaz, A.K. Kemmling, and G.N. Balerio Baclofen reestablishes striatal and cortical dopamine concentrations during naloxone-precipitated withdrawal Neurochem Int 42 2003 293 298
14. S.L. Diaz, A.K. Kemmling, C.D. Bonavita, M.C. Rubio, and G.N. Balerio Baclofen reestablishes μ-opioid receptor levels modified by morphine withdrawal syndrome in either sex Synapse 54 2004 24 29
15. A.O.S. El-Kadi, and S.I. Sharif The role of dopamine in the expression of morphine withdrawal Gen Pharmacol 30 1998 499 505
16. E.F. Espejo, M.I. Serrano, S. Caille, and L. Stinus Behavioral expression of opiate withdrawal is altered after prefrontocortical dopamine depletion in rats: monoaminergic correlates Neuropsychopharmacology 25 2001 204 212
17. 2 dopamine receptors in the expression of morphine withdrawal signs in rats Behav Pharmacol 7 1996 448 453
18. G. Gianutsos, M. Hynes, and H. Lal Enhancement of morphine-withdrawal and apomorphine-induced aggression by clonidine Psychopharmacol Commun 2 1976 165 171
19. R.E. Heikkila, A. Hess, and R.C. Duvoisin Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice Science 224 1984 1451 1453
20. M. Hu, H.S. Crombag, T.E. Robinson, and J.B. Becker Biological basis of sex differences in the propensity to self-administer cocaine Neuropsychopharmacology 29 2004 81 85
21. E.T. Iwamoto, and E.L. Way Opiate actions and catecholamines Adv Biochem Psychopharmacol 20 1979 357 407
22. K. Kantak, and K. Miczek Social, motor, and autonomic signs of morphine withdrawal: differential sensitivities to catecholaminergic drugs in mice Psychopharmacology 96 1988 468 476
23. B. Kest, C. Palmese, and E. Hopkins A comparison of morphine analgesic tolerance in male and female mice Brain Res 879 2000 17 22
24. G.F. Koob, and F.E. Bloom Cellular and molecular mechanisms of drug dependence Science 242 1988 715 723
25. R. Maldonado, J.A. Blendy, E. Tzavara, P. Gass, B.P. Roques, and J. Hanoune Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB Science 273 1996 657 659
26. C. Manzanedo, M.A. Aguilar, M. Rodriguez-Arias, and J. Miñarro Effects of dopamine antagonists with different receptor blockade profiles on morphine-induced place preference in male mice Behav Brain Res 121 2001 189 197
27. C. Missale, S.R. Nash, S.W. Robinson, M. Jaber, and M.G. Caron Dopamine receptors: from structure to function Physiol Rev 78 1998 189 225
28. T.P. Piepponen, J. Katajamäki, T. Kivastik, A. Zharkovsky, and L. Ahtee Behavioural and neurochemical sensitization of morphine-withdrawn rats to quinpirole Pharmacol Biochem Behav 54 1996 787 792
29. E. Pothos, P. Rada, G.P. Mark, and B.G. Hoebel Dopamine microdialysis in the nucleus accumbens during acute and chronic morphine, naloxone-precipitated withdrawal and clonidine treatment Brain Res 566 1991 348 350
30. R. Ranaldi, and R.A. Wise Blockade of D1 receptors in the ventral tegmental area decreases cocaine reward: possible role for dendritically released dopamine J Neurosci 21 2001 5841 5846
31. M. Rodriguez-Arias, J. Pinazo, J. Minarro, and L. Stinus Effects of SCH 23390, raclopride, and haloperidol on morphine withdrawal-induced aggression in male mice Pharmacol Biochem Behav 64 1999 123 130
32. R.H. Roth Dopamine autoreceptors: pharmacology, function and comparison with post-synaptic dopamine receptors Commun Psychopharmacol 3 1979 429 445
33. M. Samini, R. Fakhrian, M. Mohagheghi, and A.R. Dehpour Comparison of the effect of levodopa and bromocriptine on naloxone-precipitated morphine withdrawal symptoms in mice Hum Psychopharmacol 15 2000 95 101
34. Y. Shoji, J. Delfs, and J.T. Williams Presynaptic inhibition of GABAB-mediated synaptic potentials in the ventral tegmental area during morphine withdrawal J Neurosci 19 1999 2347 2355
35. M. Simonato The neurochemistry of morphine addiction in the neocortex Trends Pharmacol Sci 17 1996 410 415
36. H.S. Stock, B. Caldarone, G. Abrahamsen, D. Mongeluzi, M.A. Wilson, and R.A. Rosellini Sex differences in relation to conditioned fear-induced enhancement of morphine analgesia Physiol Behav 72 2001 439 447
37. 2 receptor agonists Psychopharmacology 108 1992 177 184
38. S. Tokuyama, H. Wakabayashi, B. Hoskins, and I.K. Ho Naloxone- precipitated changes in biogenic amines and their metabolites in various brain regions of butorphanol-dependent rats Pharmacol Biochem Behav 54 1996 461 468
39. M.R. Zarrindast, M. Habibi, S. Borzabadi, S.F. Tabaei, S.H. Yahyavi, and P. Rostamin The effects of dopamine receptor agents on naloxone-induced jumping behaviour in morphine-dependent mice Eur J Pharmacol 451 2002 287 293